About OMICS Group OMICS Group International is an

About OMICS Group OMICS Group International is an

About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology Open Access, OMICS Group publishes 400 online open access scholarly journals in all aspects of Science, Engineering, Management and Technology journals. OMICS Group has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS Group also organizes 300 International conferences annually across the globe,

where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions. About OMICS Group Conferences OMICS Group International is a pioneer and leading science event organizer, which publishes around 400 open access journals and conducts over 300 Medical, Clinical, Engineering, Life Sciences, Pharma scientific conferences all over the globe annually with the support of more than 1000 scientific associations and 30,000 editorial board members and 3.5 million followers to its credit. OMICS Group has organized 500 conferences, workshops and national

symposiums across the major cities including San Francisco, Las Vegas, San Antonio, Omaha, Orlando, Raleigh, Santa Clara, Chicago, Philadelphia, Baltimore, United Kingdom, Valencia, Dubai, Beijing, Hyderabad, Bengaluru and Mumbai. Using VBIM technique to identify drug resistance genes in ovarian cancer Tao Lu, Ph.D. Department of Pharmacology &Toxicology Department of Biochemistry & Molecular Biology Department of Medical and Molecular Genetics Experimental & Developmental Therapeutics Program

Indiana University School of Medicine Outline Background of Validation-Based Insertional Mutagenesis (VBIM) technique Example 1: VBIM technique identifies F-box leucine repeat rich protein (FBXL11) as a novel regulator of NF-B Example 2: VBIM technique and drug resistance gene discovery in ovarian cancer Book Chapter, p253-264. Cold Spring Harbor Press (2009). http://cshperspectives.cshlp.org/cgi/collection/nf-kb

Lentiviral VBIM mutagenesis method Lentiviral VBIM vector with CMV promoter ATG Enhanced expression ATG Gene ATG Dominant negative or functional domain

ATG Antisense RNA Reversible insertional mutation Lentiviral vector with loxP sites (defective promoter in LTR) LoxP LoxP + Gene

wild type Gene mutant Insertional mutation Reverted with Cre Cre

Gene Gene wild type Part I VBIM technique identifies F-box leucine repeat rich protein (FBXL11) as a novel regulator of NF-B Human cancers

Constitutive activation Baud V and Karin M. (2009).Nat Rev Drug Discov 8, 33-40. Model Stimuli NFB (Activation)

Methylation NFB NFB B Target genes FBXL11 Demethylation (Inhibition)

Lu, T et al. (2010). Proc Natl Acad Sci 107:46-51. Take-home message We successfully developed the lentiviral VBIM technique, which has broad application in a variety of signaling systems. Using VBIM technique we identified and confirmed that FBXL11 is a novel negative regulator of NF-B. Lu, T et al. (2009). Proc Natl Acad Sci 106:16339-44.

Part II Target discovery: Using VBIM to identify carboplatin resistance gene in ovarian cancer (OC) cells Background 1. Ovarian cancer is the sixth most common cause of cancer in women globally with over 200,000 cases diagnosed annually. 2. Chemotherapy resistance is a complex process using different mechanisms and pathways. However, the mechanism is NOT fully understood. Experimental Design

In our ongoing carboplatin resistance gene identification study, NCR-1, 2, 3 (Novel carboplatin resistance protein) have been identified in A2780 OC cells A2780 NCR-1 overexpressing and shRNA knockdown cells Ctrl NCR-1 NCR-1 -actin

Ctrl shNCR-1 NCR-1 -actin Wei H et al, unpublished data Effect of NCR-1 on carboplatin resistance in A2780 OC cells NCR1 Ctrl

shNCR1 Wei et al, unpublished data NCR1 is an NF-B activator in 293 cells NCR1 -actin NC R1 Ct rl+

IL 1 NC R1 +IL 1 Ct rl NC R1 Ct

rl * 1 sh NC R NC R1 Ct

rl NCR1 is an NF-B activator in A2780 OC cells Expression of NCR-1 in cancer Ovarian cancer Breast cancer Oncomine data

NCR1 expression level Correlation between NCR1 expression and OC (Tumor microarray) NCR is overexpressed in OC VBIM and high throughput screen (HTS) of drug resistance gene in OC cells Options: Plated A2780 ovarian cells

1.Multiple plates 2.Multiple drugs VBIM virus carboplatin whole genome RNAseq Oncomine TCGA

ICGC data Drug resistant mutant cells PCR and targeted RNAseq experiment Bioinformatics analysis Expression profile in

ovarian cancer cells & tissues Significance 1. Lead to the discovery of novel carboplatin resistant genes in ovarian cancer. 2. Yield mechanisms of gene-mediated carboplatin resistance, so that reversal or bypass of this resistance can be achieved by developing small chemical inhibitors in ovarian cancer. 3. In a broader scope, the findings in ovarian cancer would further shed light on mechanisms of carboplatin resistance in other cancers as well. Successful applications of VBIM technology

1. Lu T*, Jackson MW, Singhi AD, Kandel ES, Yang MJ, Zhang Y, Gudkov AV, and Stark GR*. (2009). Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NF-kB. Proc Natl Acad Sci USA. 106, 16339-16344. (*corresponding authors). 2. Lu T*, Jackson MW, Wang B, Yang M, Chance M, Miyagi M, Gudkov AV, and Stark GR*. (2010). Regulation of NF-kB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci USA. 107, 46-51. (*corresponding authors). 3. Lu T, Stark GR. (2010). Use of forward genetics to discover novel regulators of NF-kB. Cold Spring Harb Perspect Biol. a001966. 4. De S, et al. (2009). Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res. 69(20):8035-8042. 5. Guo C, et al. (2011). FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGFdependent activation of NF-kB. Proc Natl Acad Sci U S A. 108(19):7968-7973. 6. Tan MH et al. (2012). Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 131(3):849-58.

7. Cipriano R, et al. (2012).FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest. 122(9):3197210. 8. Wang B, Zhang X, Zhao Z. (2013). Validation-based insertional mutagenesis for identification of Nup214 as a host factor for EV71 replication in RD cells. Biochem Biophys Res Commun. 437(3):452-6. 9. Cipriano R et al. (2013). FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget 4(5):729-38. Acknowledgments Lu Lab, Indiana University Han Wei, Ph.D. Rasika Mundade, Ph.D. student Larry Hua, Research Scholar Yun She, B.S. Lindsey Pyron, Summer student

Case Western Reserve University Mass Spectrometry Center Dr. Benlian Wang Dr. Masaru Miyagi Dr. Mark Chance Cleveland Clinic Dr. George Stark Dr. Mark Jackson Dr. Eugene Kandel

Indiana University Dr. Lang Li Dr. Yunlong Liu Dr. George Sandusky Roswell Park Cancer Institute Dr. Andrei Gudkov Dr. Aatur Singh Harvard University Dr. Yi Zhang

THE END Let Us Meet Again We welcome you all to our future conferences of OMICS Group International Please Visit: www.omicsgroup.com www.conferenceseries.com www.pharmaceuticalconferences.com

Recently Viewed Presentations

  • Chinese Pidgin English (CPE) China Coast Pidgin (CCP)

    Chinese Pidgin English (CPE) China Coast Pidgin (CCP)

    Chinese Pidgin English (CPE) China Coast Pidgin (CCP) Origins, Context, Features J. Lloyd Ling. 455 Introduction Three Types of CPE identified in Arends ,et. al. (1994) 1.China Coast Pidgin (mainland coastal ports from Guangzhou to Shanghai) 2.
  • Monday, March 18, 2019 1.Bell-Ringer: today is a

    Monday, March 18, 2019 1.Bell-Ringer: today is a

    Monday, March 18, 2019. 1.Bell-Ringer: today is a free write -pick a topic of your choice and write HOMEWORK: SOAPSTone(go back to the blog for Friday's Power Point and make sure you have the complete answers for pages 133-134.
  • Psycholinguistics Scope - NKFUST

    Psycholinguistics Scope - NKFUST

    Psycholinguistics Scope Experimental Developmental ... 1 Cognitive Science (interdisciplinary) Cognitive Psychology (thought, memory, perception, LANGUAGE, imagery, judgment, problem solving) Psycholinguistics Experimental Developmental Comprehension Acquisition Production The Bigger Context - 2 ...
  • Statutory Interpretation Revision - Social Sciences

    Statutory Interpretation Revision - Social Sciences

    Modern day version of Mischief Rule. EU law is drafted in much broader terms than UK statutes. To ensure consistent application of European law throughout all member states, judges in the UK recognise that when applying European legislation or domestic...
  • Malthus' Theory of Population Growth

    Malthus' Theory of Population Growth

    Population Theories and Models Stay tuned for tons of IB excitement! Natural Increase= Crude Birth Rate - Crude Death Rate How you doin'? Malthus' Theory of Population Growth In 1798 Thomas Malthus published his views on the effect of population...
  • Laboratory and Clinical Services Clinical Biometrics CMC DMPK

    Laboratory and Clinical Services Clinical Biometrics CMC DMPK

    vitro/in vivo . DMPK support for discovery and development. EPA, GLP, & non-GLP studies; QA support for regulated studies. ... Less than 5 miles from NYC. ½ mile from local medical center. Near major airports and mass . transit. 36,000...
  • To Publish or not to Publish?: A Guide

    To Publish or not to Publish?: A Guide

    ….Mixed methods research is the research paradigm that (a) partners with the philosophy of pragmatism in one of its forms (left, right, middle); (b) follows the logic of mixed methods research (including the logic of the fundamental principle and any...
  • ASOA Course ID: 3808 Title: Supplemental Diagnostic Testing ...

    ASOA Course ID: 3808 Title: Supplemental Diagnostic Testing ...

    ASOA Course ID: 3808 Title: Supplemental Diagnostic Testing With Visual Electrophysiology (1 hour) read. Disclosure. ... pathway disturbances from amblyopia, glaucomas that are known to affect retinal or optic nerve function before structural loss of the retinal nerve fiber layer...